1、2022HIV MARKET REPORTThe state of HIV treatment,testing,and prevention in low-and middle-income countriesISSUE 13,NOVEMBER 2022 Clinton Health Access Initiative,Inc.(CHAI)2022DISCLAIMERThe data sources primarily used for analysis in the report include CHAI country teams,ministry of health counterpar

2、ts,stakeholder resources and conversations(e.g.Global Fund,PEPFAR,UNAIDS,Unitaid,WHO,and civil society partners),and published research.CHAI has taken precautions to verify the information shared in the report.However,the analysis in the report is not exhaustive,and the responsibility for the interp

3、retation and use of the material lies with the reader.The mention of specific companies or products does not imply CHAIs endorsement or recommendation.ACKNOWLEDGEMENTThis report was made possible through the generous support of Unitaid,with complementary support from the UK Foreign,Commonwealth&Deve

4、lopment Office,and the Bill&Melinda Gates Foundation.TABLE OF CONTENTSAPPENDIX E:REFERENCESAPPENDIX D:NOTES ON METHODOLOGYAPPENDIX C:OPTIMAL FORMULARY AND LIMITED-USE LISTAPPENDIX B:CHAI ARV BENCHMARK PRICE COMPARISON LISTAPPENDIX A:FORECASTED API DEMAND IN GA LMICSSTAY NEGATIVETREAT RIGHT:TREATMENT

5、 MONITORINGTREAT RIGHT:PEDIATRIC TREATMENTTREAT RIGHT:ADULT TREATMENTTREAT RIGHT:ADVANCED HIV DISEASETEST SMARTGENERAL TRENDSAT-A-GLANCEACRONYMS434241 40393128251814106542022 CHAI HIV Market Report:Acronyms4ACRONYMSARVAntiretroviralARTAntiretroviral therapyAmB-dAmphotericin B deoxycholateAIDSAcquire

6、d immunodeficiency syndromeAHDAdvanced HIV DiseaseAGYWAdolescent girls and young womenABCAbacavir5FCFlucytosine3TCLamivudine3LThird-line3HPThree months of weekly RPT+INH for TPT1LFirst-line2LSecond-lineATV/rAtazanavir/ritonavirAZTZidovudineCMCryptococcal meningitisCLHIVChildren living with HIVCHAICl